Advertisement

Breast Cancer

, Volume 22, Issue 5, pp 452–461 | Cite as

Relationship of serum isoflavone, insulin and adiponectin levels with breast cancer risk

  • Machiko MinatoyaEmail author
  • Goro Kutomi
  • Sumiyo Asakura
  • Seiko Otokozawa
  • Yukiko Sugiyama
  • Hirofumi Ohnishi
  • Hiroshi Akasaka
  • Tetsuji Miura
  • Mitsuru Mori
  • Koichi Hirata
Original Article

Abstract

Background

Obesity is one of the well-known risk factors of breast cancer. Accumulating evidence suggests that adiponectin, an obesity-related hormone, is inversely associated with breast cancer risk, particularly in postmenopausal women. Obesity is also associated with high levels of insulin. In addition, studies have suggested that the soy isoflavones present in the traditional Japanese diet have been associated with decreased risk of breast cancer. However, there is no study that has assessed associations between serum levels of isoflavones, insulin, adiponectin and the risk of breast cancer all together with menopausal status.

Methods

In a case–control study of 63 histologically confirmed breast cancer patients and 76 controls, serum isoflavone, insulin, and high-molecular-weight (HMW) adiponectin levels and breast cancer risk were examined for their association with breast cancer risk after adjustment for various risk factors.

Results

Women in the highest tertile of serum HMW adiponectin levels were associated with a statistically significant decreased risk for breast cancer compared with women in the lowest tertile [odds ratio (OR), 0.09; 95 % confidence interval (CI) 0.03–0.33]. This association was observed in postmenopausal women (OR 0.06; 95 % CI 0.01–0.28), but not in premenopausal women. The observed associations were independent of possible effects of insulin, body mass index, and known risk factors for breast cancer. Serum isoflavones and insulin levels were not associated with breast cancer risk.

Conclusions

This study suggests that high serum HMW adiponectin levels are significantly associated with a decreased risk for breast cancer. Our result support the hypothesis that serum adiponectin may act as a potential biomarker for breast cancer.

Keywords

Isoflavones Insulin Adiponectin Breast cancer 

Notes

Acknowledgments

This study is supported by a Grant-in-aid for Scientific Research (Project Number 24659325) from the Ministry of Education, Science, Sports and Culture of Japan.

Conflict of interest

All authors have no conflict of interest.

References

  1. 1.
    Hirabayashi Y, Zhang M. Comparison of time trends in breast cancer incidence (1973–2002) in Asia, from cancer incidence in five continents, vols IV–IX. Jpn J Clin Oncol. 2009;39:411–2.CrossRefPubMedGoogle Scholar
  2. 2.
    Matsuda T, Marugame T, Kamo K, Katanoda K, Ajiki W, Soube T. Cancer incidence and incidence rates in Japan 2005: based on data from 12 population-based cancer registries in the monitoring of cancer incidence in Japan (MCIJ) project. Jpn J Clin Oncol. 2011;41:139–47.CrossRefPubMedGoogle Scholar
  3. 3.
    Yoshiike N, Seino F, Tajima S, Arai Y, Kawano M, Furuhata T, et al. Twenty-year changes in the prevalence of overweight in Japanese adults: the national nutrition survey 1976–95. Obes Rev. 2002;3:183–90.CrossRefPubMedGoogle Scholar
  4. 4.
    Adlercreutz H, Bannwart C, Wahala K, Makela T, Brunow G, Hase T, et al. Inhibition of human aromatase by mammalian lignans and isoflavonoids phytoestrogens. J Steroid Biochem Mol Biol. 1993;44:147–53.CrossRefPubMedGoogle Scholar
  5. 5.
    Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, Itoh N, et al. Genistein, a specific inhibitor of tyrosine-specific kinases. J Biol Chem. 1987;262:5592–5.PubMedGoogle Scholar
  6. 6.
    Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, Saag PT, et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology. 1998;139:4252–63.PubMedGoogle Scholar
  7. 7.
    Onozawa M, Fukuda K, Ohtani M, Akaza H, Sugimura T, Wakabayashi K. Effects of soybean isoflavones on cell growth and apoptosis of the human prostatic cancer cell line LNCaP. J Clin Oncol. 1998;28:360–3.Google Scholar
  8. 8.
    Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. Lancet. 2001;2:133–40.CrossRefPubMedGoogle Scholar
  9. 9.
    Morimoto LM, White E, Chen Z, Chlebowski RT, Hays J, Kuller L, et al. Obesity, body b size, and risk of postmenopausal breast cancer: the women’s Health Initiative (United States). Cancer Causes Control. 2002;13:741–51.CrossRefPubMedGoogle Scholar
  10. 10.
    Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569–78.CrossRefPubMedGoogle Scholar
  11. 11.
    Bruning PF, Bonfrer JM, van Noord PA, Hart AA, de Jong-Bakker M, Nooijen WJ. Insulin resistance and breast-cancer risk. Int J Cancer. 1992;52:511–6.CrossRefPubMedGoogle Scholar
  12. 12.
    Del Goudice ME, Fantus IG, Ezzxat S, McKeown-Eyssen G, Page D, Goodwin PJ. Insulin and related factors in premenopausal breast cancer risk. Breast Cancer Res Treat. 1998;47:111–20.CrossRefGoogle Scholar
  13. 13.
    Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Madarnas Y, et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol. 2002;20:42–51.CrossRefPubMedGoogle Scholar
  14. 14.
    Stefan N, Vozarova B, Funahashi T, Matsuzawa Y, Weyer C, Lindsay RS, et al. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes. 2002;51:1884–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999;257:79–83.CrossRefPubMedGoogle Scholar
  16. 16.
    Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 2000;20:1595–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, Chao CL, et al. Plasma adiponectin levels in overweight and obese Asians. Obes Res. 2002;10:1104–10.CrossRefPubMedGoogle Scholar
  18. 18.
    Rose DP, Komninou D, Stephensen GD. Obesity, adipocytokines, and insulin resistance in breast cancer. Obes Rev. 2004;5:153–65.CrossRefPubMedGoogle Scholar
  19. 19.
    Mantzoros C, Petridou E, Dessypris N, Chavelas C, Dalamaga M, Alexe DM, et al. Adiponectin and breast cancer risk. J Clin Endocrinol Metab. 2004;89:1102–7.CrossRefPubMedGoogle Scholar
  20. 20.
    Miyoshi Y, Funahashi T, Kihara S, Taguchi T, Tamaki Y, Matsuzawa Y, et al. Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res. 2003;9:5699–704.PubMedGoogle Scholar
  21. 21.
    Chen DC, Chung YF, Yeh YT, Chaung HC, Kuo FC, Fu OY, et al. Serum adiponectin and leptin levels in Taiwanese breast cancer patients. Cancer Lett. 2005;237:109–14.CrossRefPubMedGoogle Scholar
  22. 22.
    Trujillo ME, Scherer PE. Adiponectin-journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med. 2005;257:167–75.CrossRefPubMedGoogle Scholar
  23. 23.
    Clavel-Chapelon F, E3N-EPIC Group. Differential effects of reproductive factors on the risk of pre- and postmenopausal breast cancer. Results from a large cohort of French women. Br J Cancer. 2002;86:723–7.CrossRefPubMedCentralPubMedGoogle Scholar
  24. 24.
    van der Brandt PA, Spiegelman D, Yaun SS, Adami HO, Beeson L, Folsom S, et al. Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol. 2000;152:514–27.CrossRefPubMedGoogle Scholar
  25. 25.
    Kang JH, Yu BY, Youn DS. Relationship of serum adiponectin and resistin levels with breast cancer risk. J Korean Med Sci. 2007;22:117–21.CrossRefPubMedCentralPubMedGoogle Scholar
  26. 26.
    Grossmann ME, Nkhata KJ, Mizuno NK, Ray A, Cleary MP. Effects of adiponectin on breast cancer cell growth and signaling. Br J Cancer. 2008;98:370–9.CrossRefPubMedCentralPubMedGoogle Scholar
  27. 27.
    Körner A, Pazaitou-Panayioyou K, Kelesidis I, Kelesidis I, Williams CJ, Kaprara A, et al. Total and high-molecular-weight adiponectin in breast cancer: in vitro and in vivo studies. J Clin Endocrinol Metab. 2007;92:1041–8.CrossRefPubMedGoogle Scholar
  28. 28.
    Chen DC, Chung YF, Yeh YT, Chaung HC, Kuo FC, Fu OY, et al. Serum adiponectin and leptin levels in Taiwanese breast cancer patients. Cancer Lett. 2006;237:109–14.CrossRefPubMedGoogle Scholar
  29. 29.
    Gulcelik MA, Colakoglu K, Dincer H, Dogan L, Yenidogan E, Gulcelik NE, et al. Associations between adiponectin and two different cancers: breast and colon. Asian Pacific J Cancer Prev. 2012;13:395–8.CrossRefGoogle Scholar
  30. 30.
    Tworoger SS, Eliassen AH, Kelesidis T, Colditz GA, Willett WC, Mantzoros CS, et al. Plasma adiponectin concentrations and risk of incident breast cancer. J Clin Endocrinol Metab. 2007;92:1510–6.CrossRefPubMedGoogle Scholar
  31. 31.
    Tian YF, Chu CH, Wu MH, Chang CL, Yang T, Chou YC, et al. Anthropometric measures, plasma adiponectin, and breast cancer risk. Endocr Relat Cancer. 2007;14:669–77.CrossRefPubMedGoogle Scholar
  32. 32.
    Retnakaran R, Hanley AJ, Connelly PW, Maguire G, Sermer M, Zinman B. Low serum levels of high-molecular weight adiponectin in Indo-Asian women during pregnancy: evidence of ethnic variation in adiponectin isoform distribution. Diabetes Care. 2006;29:1377–9.CrossRefPubMedGoogle Scholar
  33. 33.
    Potischman N, Swanson CA, Siiteri P, Hoover RN. Reversal of relation between body mass and endogenous estrogen concentrations with menopausal status. J Nat Can Inst. 1996;88:756–8.CrossRefGoogle Scholar
  34. 34.
    Dieudonne MN, Bussiere M, Dos Santos E, Leneveu MC, Giudicelli Y, Pecquery R, et al. Adiponectin mediates antiproliferative and apoptotic responses in human MCF7 breast cancer cells. Biochem Biophys Res Commun. 2006;345:271–9.CrossRefPubMedGoogle Scholar
  35. 35.
    Arditi JD, Venihaki M, Karalis KP, Chrous GP. Antiproliferative effect of adiponectin on MCF7 breast cancer cells: a potential hormonal like between obesity and cancer. Horm Metab Res. 2007;39:9–13.CrossRefPubMedGoogle Scholar
  36. 36.
    Jardé T, Caldefie-Chezet F, Damez M, Mishellany F, Perrone D, Penault-Llorca F, et al. Adiponectin and leptin expression in primary ductal breast cancer and in adjacent healthy epithelial and myoepithelial tissue. Histopathology. 2008;53:484–7.CrossRefPubMedGoogle Scholar
  37. 37.
    Chappell J, Leitner JW, Solomon S, Golovchenko I, Goalstone ML, Boris Draznin B. Effect of insulin on cell cycle progression in MCF-7 breast cancer cells. Direct and potentiating influence. J Biol Chem. 2001;276:38023–8.CrossRefPubMedGoogle Scholar
  38. 38.
    Wang Y, Lam JB, Lam KSL, Liu J, Lam MC, Hoo RLC, et al. Adiponectin modulates the glycogen synthase kinase-3β/β-catenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice. Cancer Res. 2006;66:11462–70.CrossRefPubMedGoogle Scholar
  39. 39.
    Kang JH, Lee YY, Yu BY, Yang BS, Cho KH, Yoon DK, et al. Adiponectin induces growth arrest and apoptosis of MDA-MB-231 breast cancer cell. Arch Pharm Res. 2005;28:1263–9.CrossRefPubMedGoogle Scholar
  40. 40.
    Verheus M, van Gils CH, Keinan-Boker L, et al. Plasma phytoestrogens and subsequent breast cancer risk. J Clin Oncol. 2007;25:648–55.CrossRefPubMedGoogle Scholar
  41. 41.
    Iwasaki M, Hamada GS, Nishimoto IN, et al. Dietary isoflavone intake and breast cancer risk in case–control studies in Japanese, Japanese Brazilians, and non-Japanese Brazilians. Breast Cancer Res Treat. 2009;116:401–11.CrossRefPubMedGoogle Scholar
  42. 42.
    Iwasaki M, Inoue M, Otani T, Sasazaki S, Kurahashi N, Miura T, et al. Plasma isoflavone level and subsequent risk of breast cancer among Japanese women: a nested case–control study from the Japan public health center-based prospective study group. J Clin Oncol. 2008;26:1677–83.CrossRefPubMedGoogle Scholar
  43. 43.
    Lampe JW. Emerging research on equol and cancer. J Nutr. 2010;140:1369S–72S.CrossRefPubMedCentralPubMedGoogle Scholar
  44. 44.
    Wu AH, Yu MC, Tseng CC, Pike MC. Epidemiology of soy exposures and breast cancer risk. Br J Cancer. 2008;98:9–14.CrossRefPubMedCentralPubMedGoogle Scholar
  45. 45.
    Mathew A, Gajalakshimi V, Rajan B, Kanimozhi V, Brennan P, Mathew BC, et al. Anthropometric factors and breast cancer risk among urban and rural women in South India: a multicentric case–control study. Br J Cancer. 2008;99:207–13.CrossRefPubMedCentralPubMedGoogle Scholar
  46. 46.
    Wu MH, Chou YC, Yu JC, Yu CP, Wu CC, Chu CM, et al. Hormonal and body-size factors in relation to breast cancer risk: a prospective study of 11,889 women in a low-incidence area. Ann Epidemiol. 2006;16:223–9.CrossRefPubMedGoogle Scholar
  47. 47.
    Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:698–712.CrossRefGoogle Scholar
  48. 48.
    Potischman N, Swanson CA, Siiteri P, Hoover RN. Reversal of relation between body mass and endogenous estrogen concentrations with menopausal status. J Natl Cancer Inst. 1996;88:756–8.CrossRefPubMedGoogle Scholar
  49. 49.
    Jernstrom H, Barrett-Connor E. Obesity, weight change, fasting insulin, proinsulin, C-peptide, and insulin-like growth factor-1 levels in women with and without breast cancer: the Rancho Bernardo Study. J Womens Health Gend Based Med. 1999;8:1265–72.CrossRefPubMedGoogle Scholar
  50. 50.
    Kaaks R, Lundin E, Manjer J, Rinaldi S, Biessy C, Söderberg S, et al. Prospective study of IGF-1, IGF-binding proteins, and breast cancer risk, in Northern and Southern Sweden. Cancer Causes Control. 2002;13:307–16.CrossRefPubMedGoogle Scholar
  51. 51.
    Mink PJ, Shahar E, Rosamond WD, Alberg AJ, Folsom AR. Serum insulin and glucose levels and breast cancer incidence: the atherosclerosis risk in communities study. Am J Epidemiol. 2002;156:349–68.CrossRefPubMedGoogle Scholar
  52. 52.
    Muti P, Quattrin T, Grant BJB, Krogh V, Micheli A, Schünemann HJ, et al. Fasting glucose is a risk factor for breast cancer: a prospective study. Cancer Epidemiol Biomark Prev. 2002;11:1361–8.Google Scholar
  53. 53.
    Kabat GC, Kim M, Caan BJ, Chlebowski RT, Ho GYF, Gunter MJ, et al. Repeated measures of serum glucose and insulin in relation to postmenopausal breast cancer. Int J Cancer. 2009;125:2704–10.CrossRefPubMedGoogle Scholar
  54. 54.
    Ogasawara M, Sirbasku DA. A new serum-free method of measuring growth factor activities for human breast cancer cells in culture. In Vitro Cell Dev Biol. 1988;24:911–20.CrossRefPubMedGoogle Scholar
  55. 55.
    Milazzo G, Giorgino F, Damante G, Sung C, Stampfer MR, Vigneri R, et al. Insulin receptor expression and function in human breast cancer cell lines. Cancer Res. 1992;52:3924–30.PubMedGoogle Scholar
  56. 56.
    Gliozzo B, Sung CK, Scalia P, Papa V, Frasca F, Sciacca L, et al. Insulin-stimulated cell growth in insulin receptor substrate-1-deficient ZR-75-1 cells in mediated by a phosphatidylinositol-3-kinase- independent pathway. J Cellular Biochem. 1998;70:268–80.CrossRefGoogle Scholar
  57. 57.
    Malaguarnera R, Sacco A, Voci C, Pandini G, Vigneri R, AntoninoBelfiore A. Proinsulin binds with high affinity the insulin receptor isoform A and predominantly activates the mitogenic pathway. Endocrinol. 2012;153:2152–63.CrossRefGoogle Scholar
  58. 58.
    Osborne CK, Monaco ME, Lippman ME, Kahn CR. Correlation among insulin binding, degradation, and biological activity in human breast cancer cells in longterm tissue culture. Cancer Res. 1987;38:94–102.Google Scholar
  59. 59.
    Sepp-Lorenzino L, Rosen N, Lebwohl DE. Insulin and insulin-like growth factor signaling are defective in the MDA-MB-468 human breast cancer cell line. Cell Growth Differ. 1994;5:1077–83.PubMedGoogle Scholar
  60. 60.
    Belfiore A, Costantino A, Frasca F, Pandini G, Mineo R, Vigneri P, et al. Overexpression of membrane glycoprotein PC-1 in MDA-MB-231 breast cancer cells in associated with inhibition of insulin receptor tyrosine kinase activity. Mol Endocrinol. 1996;10:1318–26.PubMedGoogle Scholar
  61. 61.
    Ward H, Chapelais G, Kuhnle GG, Ruben R, Khaw KT, Bingham S. European prospective into cancer-Norfolk cohort. Breast cancer risk in relation to urinary and serum biomarkers of phytoestrogen exposure in the European prospective into Cancer-Norfolk cohort study. Breast Cancer Res. 2008;10:R32.CrossRefPubMedCentralPubMedGoogle Scholar
  62. 62.
    Oh S, Park CY, Lee E, Yoon Y, Lee E, Park S, et al. Adipokines, insulin resistance, metabolic syndrome, and breast cancer recurrence: a cohort study. Breast Cancer Res. 2011;13:R34.CrossRefPubMedCentralPubMedGoogle Scholar
  63. 63.
    Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T, Berger JP, et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem. 2004;279:12152–62.CrossRefPubMedGoogle Scholar
  64. 64.
    Waki H, Yamauchi T, Kamon J, Ito Y, Uchida S, Kita S, et al. Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J Biol Chem. 2003;278:40352–63.CrossRefPubMedGoogle Scholar
  65. 65.
    Fisher FF, Trujillo ME, Hanif W, Barnett AH, McTernan PG, Scherer PE, et al. Serum high molecular weight complex of adiponectin correlates better with glucose tolerance than total serum adiponectin in Indo-Asian males. Diabetologia. 2005;48:1084–7.CrossRefPubMedGoogle Scholar
  66. 66.
    Hao G, Li W, Guo R, Yang JG, Wang Y, Tian Y, et al. Serum total adiponectin level and the risk of cardiovascular disease in general population: a meta-analysis of 17 prospective studies. Atherosclerosis. 2013;228:29–35.CrossRefPubMedGoogle Scholar
  67. 67.
    Mohamad AS, Taher AN, Mohamad AA, El-Nasr MS. Evaluation of serum adiponectin level in Egyptian breast cancer patients before and after treatment. Med J Cairo Univ. 2010;78:67–76.Google Scholar
  68. 68.
    Pfeiler G, Konigsberg R, Hadji P, Fitzal F, Tea MKM, Vogl S, et al. The impact of estrogen depletion by aromatase inhibitors on adiponectin serum levels in postmenopausal patients with breast cancer. J Clin Oncol (meeting abstracts). 2013;31(suppl):e11601.Google Scholar

Copyright information

© The Japanese Breast Cancer Society 2013

Authors and Affiliations

  • Machiko Minatoya
    • 1
    Email author
  • Goro Kutomi
    • 2
  • Sumiyo Asakura
    • 1
  • Seiko Otokozawa
    • 1
  • Yukiko Sugiyama
    • 1
  • Hirofumi Ohnishi
    • 1
  • Hiroshi Akasaka
    • 3
  • Tetsuji Miura
    • 3
  • Mitsuru Mori
    • 1
  • Koichi Hirata
    • 2
  1. 1.Department of Public HealthSapporo Medical University School of MedicineChuo-kuJapan
  2. 2.Department of Surgery, Surgical Oncology and ScienceSapporo Medical University School of MedicineSapporoJapan
  3. 3.Department of Cardiovascular, Renal and Metabolic MedicineSapporo Medical University School of MedicineSapporoJapan

Personalised recommendations